Integra Lifesciences Holdings (IART)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$14.12-4.72%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · IART
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.5% |
| Our one-year growth estimate | diamond | 0.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 40.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
IART — credit agreement
Dated 2026-10-19
Entry Into a Material Definitive Agreement On October 19, 2026, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer (the “Credit Agreement”). In addition, on October 19, 2026 the Company completed a private unregistered offering of $450 million aggregate principal amount of its 9.500% Senior Secured Notes due 2033…
Why it matters: The flood cut Q3 revenue by about $7 million. Full output would ease the main supply hit.
Supportive ifBy Q2 2027, Integra reports full production in Cincinnati. It reports no more revenue loss from floods.
Worry ifFull production slips past Q2 2027, or flood-related revenue losses top the stated Q4 range of $15 million to $20 million.
Why it matters: Integra guided to Q4 revenue of $413 million to $433 million. A miss would deepen the expected decline.
Worry ifQ4 2026 revenue is below $413 million, the low end of the stated range.
Less concerning ifQ4 2026 revenue is at least $413 million and within the stated $413 million to $433 million range.
Why it matters: The segment fell 2.2% in Q3. Growth would show that weaker wound sales are easing.
Supportive ifTissue Reconstruction revenue grows year over year in a reported quarter after Q3 2026.
Worry ifTissue Reconstruction revenue falls at least 2.2% year over year again in the next reported quarter.
Why it matters: The new site is part of Integra's quality and supply work. Sales would mark a clear step from setup to output.
Supportive ifIntegra reports commercial revenue from Braintree in Q4 2026.
Worry ifIntegra reports no commercial revenue from Braintree by the end of Q4 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$179 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $461 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,035 loss on $10,000 · 40.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.